Appendix Table F27. Pharmacological treatments for female UI (continued)

Reference study, country, sample	Inclusion criteria	Exclusion criteria	Active	Control	Sponsorship	Conflict of interest
Zinner, 2011[410] RCT Not reported N: 944	Male and female subjects aged >= 18 years with symptoms of OAB for >=6 months who met the following criteria (based on a 3-day patient diary): urinary frequency >=30 toilet voids/3 days (i.e. average >=10 toilet voids/day); >=1 "severe" urgency severity rating/3 days (as measured by the Indevus Urgency Severity Scale [IUSS]); and >=3 UUI episodes/3 days (i.e., average >=1 UUI episodes/day).	Subjects with a total voided volume >3000 ml/day or a mean volume voided/void >250ml ; subjects with predominantly stress, insensate, or overflow incontinence; history of neurogenic bladder, indwelling or intermittent catheterization, significant renal disease (serum creatinine >1.5mg /dL), uninvestigated hematuria or urinary tract infection during screening, or a history of >=3 urinary tract infections in the previous 12 months; clinically significant urinary retention (defined as post-void residual urine volume >100mL), cancer, interstitial cystitis.	Trospium for 48 weeks	Trospium for 36 weeks	Sponsored by Allergan Inc. and Endo Pharma-ceuticals (formerly Indevus Pharma-ceuticals, Inc.). Neil Reynolds, Monica Grandison, and Sushma Soni of in Science commun-ications provided editorial support funded by Allergan, Inc.	None

Abbreviation: NR = Not reported